Ya Ding
State Key Laboratory Of Oncology In South China
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Combination of Postoperative Adjuvant Chemoradiotherapy and Immune Checkpoint Inhibitors Significantly Prolongs Recurrence-Free Survival in Sinonasal Mucosal Melanoma.
Journal: Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
Published: March 31, 2026
Clinical outcomes of intrathecal anti-PD-1 therapy with or without whole-brain radiotherapy in melanoma leptomeningeal metastasis: a multicenter retrospective study.
Journal: Frontiers in immunology
Published: March 14, 2026
Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 17, 2025
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Journal: The Lancet. Oncology
Published: December 07, 2023
A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors.
Journal: Nature communications
Published: January 20, 2023
Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.
Journal: Frontiers in immunology
Published: October 29, 2022
An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets.
Journal: Frontiers in immunology
Published: August 05, 2022
Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.
Journal: Journal of cancer research and clinical oncology
Published: June 13, 2022
HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Journal: Frontiers in immunology
Published: March 22, 2022
Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy.
Journal: Scientific reports
Published: February 01, 2022
Whole-exome sequencing in clear cell sarcoma of soft tissue uncovers novel prognostic categorization and drug targets.
Journal: Clinical and translational medicine
Published: July 13, 2021
Last Updated: 09/26/2026